Tom is Co-Founder & Executive Chairperson of Molecule to Medicine (MTM), a UK, EU and Australian based organisation that brings together entrepreneurs and experts to co-create and scale biotech companies within MTM’s global ecosystem. Current MTM portfolio companies include Grey Wolf Therapeutics, Pathios Therapeutics, ThirtyFiveBio, Melio Bio, Lucia Bio and Curlew Bio. From 2006-2015 he was CEO of Spinifex Pharmaceuticals, an Australian and US biotech company developing first in class treatments for chronic pain without central nervous system side-effects. Spinifex Pharmaceuticals was purchased by Novartis in 2015 for approximately US$700 million. Previous positions include Vice President, Drug Development at Starpharma Holdings. He holds BSc (Hons) and PhD degrees from Monash University, Australia and completed his postdoctoral training at The University of Oxford.